Delfi Diagnostics, a startup focusing on using blood draws for cancer detection, has appointed Susan Tousi, Illumina’s chief commercial officer, as its new CEO. This marks her as the fourth top executive to leave Illumina since June. Tousi will start her role next week to lead the company as it expands its commercial efforts. Founding CEO Victor Velculescu will remain on the board to guide research programs. The move by Delfi is to enlarge its commercial efforts and strengthen its lung cancer test launched last fall. This comes as Illumina’s ambition to enter the liquid biopsy market was thwarted after having to divest Grail due to regulatory issues.
Source link
Susan Tousi leaves Illumina to head cancer liquid biopsy startup
